<DOC>
	<DOC>NCT00345800</DOC>
	<brief_summary>To monitor for endocrine changes in response to treatment of cataplexy with Xyrem, to focus on the hypothalamic pituitary axis and to confirm the safety of Xyrem on potential endocrine changes.</brief_summary>
	<brief_title>Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes</brief_title>
	<detailed_description />
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Cataplexy</mesh_term>
	<mesh_term>Sodium Oxybate</mesh_term>
	<criteria>Narcoleptic patients with cataplexy Subjects not diagnosed with narcolepsy with cataplexy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Endocrine Evaluation cataplexy</keyword>
	<keyword>sodium oxybate (xyrem)</keyword>
</DOC>